Key Developments: Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

11:35am EDT
Price Change (% chg)

€0.14 (+3.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Stentys wins tender which could be for more than 1,000 stents
Monday, 20 Oct 2014 12:34pm EDT 

Stentys SA:Wins SGH tender which could be for more than 1,000 stents.SGH tender is centralised purchase programme put in place by Gulf States' Council for Cooperation.SGH tender programme is renewed each year for 12 months.  Full Article

Stentys creates branch office in Dubai
Thursday, 25 Sep 2014 11:45am EDT 

Stentys SA:Announces creation of branch office in Dubai.  Full Article

Stentys announces positive results of Apposition III study
Tuesday, 16 Sep 2014 12:12pm EDT 

Stentys SA:Announces positive results of 1,000 patient Apposition III clinical study at two years after treatment of severe heart attack.At two years, MACE (defined as the composite of cardiac death, target-vessel myocardial infarction, emergent by-pass and clinically driven target lesion revascularization), was 11.2 pct compared to 9.3 pct at one year.Cardiac death at two years was 2.3 pct compared to 2.0 pct at one year.  Full Article

Stentys signs first distribution agreements in South America
Wednesday, 9 Jul 2014 11:46am EDT 

Stentys SA:Signs first distribution contracts in Argentina, Chile and Colombia.Contracts signed within company strategy to expand commercial presence into Latin American coronary stent market.  Full Article

Stentys SA completes acquisition of Cappella Peel Away Inc
Thursday, 12 Jun 2014 01:00pm EDT 

Stentys SA:Says it presented the final terms of the acquisition of Cappella Peel Away Inc. and of its assets relating to a stent delivery system for a total amount of 1 million euro in stock and cash.  Full Article

Stentys SA to acquire Stent Delivery Technology
Wednesday, 4 Jun 2014 11:45am EDT 

Stentys SA:Signs acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a stent delivery system.Financial terms were not disclosed.  Full Article

Stentys SA presented final results from APPOSITION IV study
Tuesday, 20 May 2014 07:15am EDT 

Stentys SA:Presented final results from APPOSITION IV study of its new Self-Apposing sirolimus-eluting stent (SES) during Hotline session at EuroPCR conference in Paris.APPOSITION IV enrolled 152 patients experiencing ST-elevation myocardial infarction (STEMI) and was first clinical trial to evaluate novel Self-Apposing sirolimus-eluting stent, which was compared to Medtronic`s Resolute zotarolimus-eluting stent at two different time points, 4 and 9 months.Evaluation was based on two imaging modalities, Quantitative Coronary Angiography (QCA) to measure difference in artery diameters between implantation and follow-up, and Optical Coherence Tomography (OCT).Results confirm that arteries with STENTYS SES healed faster than with balloon-expandable drug-eluting stents.At 9 months, STENTYS SES showed no reduction in artery lumen diameter (Late Lumen Loss of 0.04mm ± 0.43 under QCA) with near perfect arterial healing (99 pct covered struts at 9 months under OCT), demonstrating stent efficacy and safety.  Full Article

Stentys secures standby equity facility
Wednesday, 14 May 2014 11:45am EDT 

Stentys SA:Enters into standby equity facility with Societe Generale, exercisable by tranches at Stentys' discretion.At the request of Stentys, Societe Generale is committed to subscribe to successive capital increases over next 36 months, within global limit of 1,000,000 shares (i.e. 9.0 pct of the shares currently outstanding).For each tranche, issue price will equal volume weighted average share price of three trading days preceding effective date of purchase with discount capped at 5 pct.Stentys has no minimum drawdown obligation.  Full Article

Stentys SA's self-apposing stent featured in new article published by Journal of the American College of Cardiology
Tuesday, 29 Apr 2014 11:45am EDT 

Stentys SA:Says Journal of the American College of Cardiology (JACC) published paper entitled “Mechanisms, Pathophysiology, and Clinical Aspects of Incomplete Stent Apposition,” which highlights STENTYS’ Self-Apposing Stent among devices to minimize stent malapposition in clinical practice.Authors advise that devices, such as STENTYS’ Self-Apposing stent, which already demonstrated an early reduction of ISA compared with balloon-expandable stents during primary PCI, can reduce malapposition and potentially harmful consequences with which it is associated.  Full Article

Stentys to propose share repurchase program
Sunday, 20 Apr 2014 08:00pm EDT 

Stentys SA:To propose terms of share repurchase program to annual general meeting.Program would authorize repurchase of up to 10 pct of capital.Maximum price per share 35 euros.Total maximum that could be spent 38,978,502.50 euros.Authorization valid for 18 months.  Full Article

Search Stocks